Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in renal transplant recipients with PTDM
NCT03157414Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Nov 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-transplantation diabetes mellitus (PTDM) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Weighted mean glucose at 24 weeks. Started Nov 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
post-transplantation diabetes mellitus (PTDM)
Beyond the preview
Go deeper on NCT03157414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157414.